Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in terms of bowel function, urinary symptoms, or sexual function. These findings were presented at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results may help inform the decision-making process for localized prostate cancer treatment.
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood.
Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper-Tract Urothelial Carcinoma
In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper-tract urothelial carcinoma.
Breast Shrinkage Following Breast-Conserving Therapy
Breast-conserving therapy, including radiation therapy, could lead to a progressive reduction in breast size over time among women with early-stage breast cancer, according to a recent study published by Becker et al in Plastic and Reconstructive Surgery.
Local Excision May Be Feasible in Patients With Low Rectal Adenocarcinoma
Chemotherapy followed by local excision may be effective in patients with node-negative low rectal adenocarcinoma, according to new findings presented by Buettner et al at the 2025 Society of Surgical Oncology (SSO) Annual Meeting.
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
Ramy Sedhom and colleagues on Optimizing Cancer Care for Older Adults
Ilana Hellmann: Reflections on a Father’s Cancer Journey
Connor J. Kinslow and colleagues on Breast Implant–Related Cancers
Lorcan Ruane and colleagues on Cardiotoxicity: How Far Have We Come?
Sponsored Content
Sponsored by Lilly Medical Affairs
The Critical Role of Navigators in Improving Access to First-Line Precision Oncology Therapies for Advanced NSCLC
SPONSORED BY BREAST CANCER INDEX® BIOTHERANOSTICS, INC. A HOLOGIC COMPANY
Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-MakingMore Top Stories
New Reports Assess Oncology Workforce Well-Being, Propose Solutions to Address Burnout
Physician burnout has increased significantly in the past decade, and organizational strategies are vital to improve physician well-being, according to new research from ASCO. This compilation includes reports on the state of professional well-being among oncologists in 2023, burnout trends among...
Patterns of ICI Use and Survival Outcomes in Metastatic Colorectal Cancer
In a U.S. population–based cohort study reported in JAMA Network Open, Bari et al identified patterns of immune checkpoint inhibitor (ICI) use and survival outcomes among patients with metastatic colorectal cancer seen in routine clinical practice. The investigators stated: “…ICIs have been...
CMS Expects Between 750,000 to 2 Million to Lose Coverage If ACA Proposal Is Implemented
On March 10, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Marketplace Integrity and Affordability Proposed Rule aimed at addressing improper enrollments in the Affordable Care Act (ACA) Health Insurance Marketplace. This is the first proposed rule released under the new ...
Results Announced From Phase II VERITAC-2 Clinical Trial in Breast Cancer
Arvinas, Inc. and Pfizer Inc. recently announced results from the randomized phase III VERITAC-2 clinical trial (ClinicalTrials.gov identifier NCT05654623) evaluating vepdegestrant monotherapy vs fulvestrant in adults with estrogen receptor–positive, HER2-negative advanced or metastatic breast...
NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma
A novel cell therapy approach using cord blood–derived natural killer (NK) cells precomplexed with the CD30/CD16A bispecific antibody AFM13 may be safe and generate responses in patients with refractory CD30-positive lymphomas, according to a recent study published by Nieto et al in Nature...
Screening Was Key to the Early Detection of My Prostate Cancer
As a Native American and former president of the Seneca Nation of Indians, I am keenly aware of the disparities in cancer care we face in accessing screening and treatment, which results in worse survival rates compared with those of racial and ethnic populations.1 Native American and Alaska Native ...
Study Identifies Biologic Reasons for Selective Benefit of PARP Inhibitors
A newfound role for the cancer gene BRCA2 suggests why only select patients have benefited from treatment with PARP1 inhibitors to date. The results of a study by investigators at NYU Langone Health were recently published in the journal Nature. In brief, PARP inhibitors act by impairing...
